Fumiko Axelrod
Overview
Explore the profile of Fumiko Axelrod including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Garg P, Chan K, Yuan T, Lujan Hernandez A, Han Z, et al.
PLoS One
. 2024 Jun;
19(6):e0301223.
PMID: 38837964
New immune checkpoints are emerging in a bid to improve response rates to immunotherapeutic drugs. The adenosine A2A receptor (A2AR) has been proposed as a target for immunotherapeutic development due...
2.
Peterson S, Juliana C, Hu C, Chai J, Holliday C, Chan K, et al.
Diabetes
. 2023 Jun;
72(9):1320-1329.
PMID: 37358194
Article Highlights: Patients with the most common and severe form of diazoxide-unresponsive congenital hyperinsulinism (HI) require a pancreatectomy. Other second-line therapies are limited in their use because of severe side...
3.
Peterson S, Hutchings C, Hu C, Mathur M, Salameh J, Axelrod F, et al.
Expert Opin Drug Discov
. 2023 Mar;
18(4):417-428.
PMID: 36992620
Introduction: G protein-coupled receptors (GPCRs) are the target of one-third of all approved drugs; however, these drugs only target about one-eighth of the human repertoire of GPCRs. GPCRs regulate a...
4.
Yuan T, Garg P, Wang L, Willis J, Kwan E, Lujan Hernandez A, et al.
MAbs
. 2021 Dec;
14(1):2002236.
PMID: 34967699
Coronavirus disease 2019 (COVID-19) is an evolving global public health crisis in need of therapeutic options. Passive immunization of monoclonal antibodies (mAbs) represents a promising therapeutic strategy capable of conferring...
5.
Yuan T, Lujan Hernandez A, Keane E, Liu Q, Axelrod F, Kailasan S, et al.
Antib Ther
. 2021 Apr;
3(3):167-178.
PMID: 33912793
Background: Development of successful neutralizing antibodies is dependent upon broad epitope coverage to increase the likelihood of achieving therapeutic function. Recent advances in synthetic biology have allowed us to conduct...
6.
Liu Q, Garg P, Hasdemir B, Wang L, Tuscano E, Sever E, et al.
MAbs
. 2021 Mar;
13(1):1893425.
PMID: 33706686
G protein-coupled receptors (GPCRs) are a group of seven-transmembrane receptor proteins that have proven to be successful drug targets. Antibodies are becoming an increasingly promising modality to target these receptors...
7.
Chartier C, Raval J, Axelrod F, Bond C, Cain J, Dee-Hoskins C, et al.
Cancer Res
. 2016 Jan;
76(3):713-23.
PMID: 26719531
Deregulation of the β-catenin signaling has long been associated with cancer. Intracellular components of this pathway, including axin, APC, and β-catenin, are frequently mutated in a range of human tumors,...
8.
Yen W, Fischer M, Axelrod F, Bond C, Cain J, Cancilla B, et al.
Clin Cancer Res
. 2015 May;
21(9):2084-95.
PMID: 25934888
Purpose: The Notch pathway plays an important role in both stem cell biology and cancer. Dysregulation of Notch signaling has been reported in several human tumor types. In this report,...
9.
Gurney A, Axelrod F, Bond C, Cain J, Chartier C, Donigan L, et al.
Proc Natl Acad Sci U S A
. 2012 Jul;
109(29):11717-22.
PMID: 22753465
The Wnt/β-catenin pathway, which signals through the Frizzled (Fzd) receptor family and several coreceptors, has long been implicated in cancer. Here we demonstrate a therapeutic approach to targeting the Wnt...
10.
Hoey T, Yen W, Axelrod F, Basi J, Donigian L, Dylla S, et al.
Cell Stem Cell
. 2009 Aug;
5(2):168-77.
PMID: 19664991
Previous studies have shown that blocking DLL4 signaling reduced tumor growth by disrupting productive angiogenesis. We developed selective anti-human and anti-mouse DLL4 antibodies to dissect the mechanisms involved by analyzing...